Danaher (DHR) Earnings Date & Reports

Key Takeaways

• Adjusted diluted earnings per share (EPS, or profit per share) rose about 8% year over year to $1.94, ahead of the roughly $1.83 consensus estimate.
• Revenue increased 5.5% to $6.3 billion, with core revenue up 3.0% (4.5% excluding respiratory testing).
• Management raised full-year 2026 adjusted EPS guidance to $8.45–$8.60 while narrowing core revenue growth to 3%–4%.
• Delayed bioprocessing shipments pushed more than $100 million of revenue into 2027, weighing on the biotechnology segment.
• Shares fell roughly 14% on the news despite the earnings beat, reflecting investor concern over the revenue outlook.

Earnings Context and Why It Matters

Danaher is a diversified life sciences and diagnostics leader whose quarterly results serve as a barometer for biopharma spending and bioprocessing demand. After a prolonged biotech funding downturn, investors have been watching closely for signs of a durable recovery. The second quarter delivered that signal in parts—core growth accelerated from the first quarter—but the combination of customer-driven bioprocessing shipment delays and a reduced revenue outlook reset expectations. The report matters because it reveals both the strength of Danaher's life sciences franchise and the lingering unevenness across its end markets heading into the back half of the fiscal year.

Reported Results

For the second quarter ended June 26, 2026, Danaher reported net earnings of $870 million, or $1.23 per diluted share under generally accepted accounting principles (GAAP), up 60% year over year. On a non-GAAP (adjusted) basis, diluted EPS grew 8.0% to $1.94, exceeding the consensus estimate of approximately $1.83.

Revenue increased 5.5% to $6.3 billion. Core revenue rose 3.0% year over year, while core revenue excluding respiratory testing grew 4.5%—a roughly 150-basis-point acceleration from the first quarter. By segment, core revenue in Life Sciences climbed 5.5%, Biotechnology rose 2.5%, and Diagnostics grew 2% (5% excluding respiratory testing). Free cash flow reached $1.3 billion in the quarter.

On guidance, Danaher raised its full-year 2026 adjusted diluted EPS outlook to a range of $8.45 to $8.60, up from $8.35 to $8.55, while lowering the top end of its core revenue growth range to 4% (from 6%), maintaining the 3% lower end.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Danaher, it can help narrow the universe of potential ideas across the life sciences and diagnostics space.

Market Reaction and Investor Sentiment

The market's response was notably negative despite an earnings beat. Danaher shares fell roughly 14% on the day, as investors focused less on the profit surprise and more on the cut to the full-year core revenue growth outlook and the weaker-than-expected biotechnology revenue. Analysts noted that bioprocessing growth and the segment's second-half trajectory would remain the central focus, even with the raised profit forecast. The reaction underscores how sensitive the stock has become to the pace of bioprocessing recovery and to any signal that customer order timing—rather than underlying demand—is driving results.

Forward Outlook and Key Factors to Monitor

Looking ahead, the key question is whether delayed bioprocessing orders convert into revenue and whether underlying demand holds. Management said bioprocessing orders grew by a mid-teens percentage in the quarter, suggesting the timing issue was concentrated among a few large commercial customers rather than a broad slowdown.

Investors will also be watching the respiratory testing headwind, which management expects to subtract roughly 250 basis points from third-quarter core revenue growth. This is a known, temporary drag, but it could continue to cloud headline numbers in the near term.

Beyond the quarter, the integration of the earlier-than-expected Masimo acquisition and the pending StatLab transaction represent catalysts worth monitoring. Both are expected to be accretive to adjusted EPS, but execution will matter.

Finally, demand signals across high-growth markets—including mid-single-digit growth in China—and the trajectory of biotech funding will remain important barometers for whether Danaher can sustain the core growth acceleration it showed in the second quarter.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations